Proteomics & phosphoproteomics
Measuring the proteins in a tumour, which is what drugs actually hit, rather than the genes that encode them.
Mass-spectrometry proteomics (CPTAC) reveals pathway activity and ADC target abundance that transcript levels do not predict. Quantitative IHC and mass-spec assays of HER2 and TROP2 aim to improve ADC patient selection.
How it works
Liquid chromatography tandem mass spectrometry with isobaric labelling quantifies proteins and phosphosites.
- Direct measurement of drug targets and signalling
- Throughput and standardisation
Latest papers
topQuery for this technology: (TITLE:"proteomics" OR ABSTRACT:"proteomics" OR TITLE:"proteogenomic" OR ABSTRACT:"proteogenomic" OR TITLE:"phosphoproteomics" OR ABSTRACT:"phosphoproteomics") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Proteomics & phosphoproteomics, not a curated reading list.
Pages like this
not linked directly; found by shared links- TechnologySingle-cell & spatial profiling
Shares Elucidate Bio, Find the parts of a tumour the drug never reaches, A global rapid tissue donation network for metastatic disease, Spatial-omics-guided treatment selection.
- CompanyNurix Therapeutics
Shares Find E3 ligases that only tumours have, and build degraders around them, Screen glue-like compounds against every cancer cell line and publish it.
- CompanyKymera Therapeutics
Shares Find E3 ligases that only tumours have, and build degraders around them, Screen glue-like compounds against every cancer cell line and publish it.
- TechnologyWhole-exome & whole-genome sequencing
Shares Li Ding, A global rapid tissue donation network for metastatic disease, EMBL's European Bioinformatics Institute, Uppsala University Hospital / Uppsala University.